Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis; Dual Biologic and Small Molecule Therapy for Refractory IBD; Post-Operative Crohn's; Use of Novel Biomarkers in Clinical Practice; Clinical Trials; Social Media in IBD; IBD Medical Education
Teaching
Assistant Professor
(2021)
School of Medicine,
Medicine
Gastroenterology; Inflammatory Bowel Disease
Publications
Berinstein JA, Karl T, Patel A, Dolinger M, Barrett TA, Ahmed W, Click B, Steiner CA, Dulaney D, Levine J, Hassan SA, Perry C, Flomenhoft D, Ungaro RC, Berinstein EM, Sheehan J, Cohen-Mekelburg S, Regal RE, Stidham RW, Bishu S, Colombel JF, Higgins PDR. Effectiveness of Upadacitinib for Patients with Acute Severe Ulcerative Colitis: A Multi-Center Experience. Am J Gastroenterol. 2024 Jan 26. [Epub ahead of print] PubMed PMID: 38275248
Smith E, Ahmed W, Battat R, et al. The Relationship Between the Endoscopic Healing Index, Fecal Calprotectin, and Magnetic Resonance Enterography in Crohn’s Disease. J Clin Gastroenterol. 2023 Aug
Ahmed W, Ben-Horin S, Charabaty A, et al. De-escalation of IBD Combination Therapy in Patients with Crohn’s Disease. Gastroenterology and Endoscopy News. 2023 Jun
Ahmed W, Billing W, Stump TE, Strobel T, Sagi S, Fischer M, Bohm M. Opioid Legislation in Patients With Inflammatory Bowel Disease: A State-wide Retrospective Cohort Study. Inflamm Bowel Dis. 2023 Sep 1;29(9):1355-1361. PubMed PMID: 36271877
Pan Y, Ahmed W, Battat R, et al. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Post-Operative Crohn’s Disease. Inflammatory Bowel Diseases. 2022 Feb
Ahmed W. Breaking the Therapeutic Ceiling: Dual Biologic or Small Molecule Therapy for Refractory Inflammatory Bowel Disease. Crohn’s & Colitis 360. 2022 Feb
Ahmed W, Billings W, Bohm M, et al. Opioid Prescribing Legislation Does Not Decrease Opioid Use in Patients with Inflammatory Bowel Disease: A State-Wide Retrospective Cohort Study. Inflammatory Bowel Diseases. 2022 Oct
Johnson A, Ahmed W, Dulai P, et al. The Real-Work Effectiveness and Safety of Ustekinumab in the Treatment of Crohn’s Disease: Results from the SUCCESS Consortium. Am J Gastroenterol. 2022 Sep
Ahmed W, Galati J, Battat R, et al. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. 2021 Mar
Ahmed W, Scott F. Closing the Gap: The Real-World Risk of Serious Infections with Vedolizumab in Comparison with Anti-TNF therapy in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. 2021 May
Lukin D, Ahmed W, Longman R, et al. No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects with IBD. Clinical Gastroenterology and Hepatology. 2021 Jun
Ahmed W, Taft T, Charabaty A. Social Media in Inflammatory Bowel Disease: the Patient and Physician Perspective. Current Opinion in Gastroenterology. 2021 Jul
Ahmed W, Ali S, Charabaty A. Fatigue in Inflammatory Bowel Disease. Gastroenterology and Endoscopy News. 2021 Aug
Lai D, Ahmed W, Longman R, et al. Joint Disease Activity Score for IBD-Associated Peripheral Spondyloarthritis Stratifies Therapeutic Response. Gastro Hep Advances. 2021 Dec
Ahmed W, Lukin D. A Step Towards Informed Positioning of Advances Therapies for Moderate-to-Severe Crohn’s Disease. Lancet Gastroenterol Hepatol. 2021 Dec.